Salarius Pharmaceuticals, Inc. has announced an agreement to merge with Decoy Therapeutics. The transaction involves Salarius merging with Decoy through a series of mergers, resulting in Decoy becoming a wholly-owned subsidiary of Salarius. The merger is structured as a stock-for-stock exchange, where all of Decoy's outstanding equity interests will be swapped for Salarius common and newly designated Series A Preferred Stock. The preferred stock is intended to have economic rights similar to Salarius common stock but with limited voting rights. The successful completion of the merger is subject to certain conditions, including a minimum of $6.0 million in proceeds from future offerings and maintaining the listing of Salarius' common stock on Nasdaq. Salarius has also adjusted the exercise price of previously issued warrants and issued additional warrants, reflecting strategic adjustments in preparation for the merger.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Salarius Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-041043), on August 22, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.